MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/21/2018
Start Date:August 31, 2015
End Date:July 1, 2019
Contact:US Medical Information
Phone:888-275-7376

Use our guide to learn which trials are right for you!

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose
levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means
the study drug has not previously been given to humans or has only been given to a limited
number of people, although it has been extensively studied in animals. Based on this
information, it is hoped to find out which dose could be best for the treatment of patients.
There are two parts of this research study: a dose-escalation part and an expansion part.
Dose escalation means that the first people taking part in the study will receive low doses
of the study drug, and as more people take part, the additional participants will receive a
higher dose. This is done to find the safest dose for the study drug. Expansion means that
after the dose-escalation part of the study has looked at the safety and effectiveness of
different doses, many more people will be invited to take part in the study and will receive
the study drug at the safest dose. Additional purposes of the study are to find out whether
the study drug has anti-cancer effects and how the study drug is processed by the body.

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group
expansion in selected solid tumor indications. The current trial is composed of a standard
dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each
dose level depending on the occurrence of dose limiting toxicities (DLTs), followed by a
consecutive parallel-group expansion in selected solid tumor indications. Cohorts of 3
subjects with metastatic or locally advanced solid tumors, for which no standard effective
therapy exists or standard therapy has failed, will receive MSB0011359C (M7824) at escalating
dose levels. After determination of the Maximum tolerated dose (MTD), enrollment in several
expansion cohorts will be opened to determine the safety, pharmacokinetic (PK) /
Pharmacodynamic, and clinical activity of MSB0011359C (M7824). Subjects who have experienced
a confirmed complete response (CR) should continue treatment through the end of 12 months,
although additional treatment is possible. In the case of progressive disease (PD), subjects
should continue treatment through their next tumor assessment. Additional indications will be
planned based on emerging data in the field.

Inclusion Criteria:

- Ability to understand the purpose of the study, provide signed and dated informed
consent, and able to comply with all procedures

- Male or female subjects aged greater than or equal to (>=) 18 years

- Life expectancy >= 12 weeks as judged by the Investigator

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry

- Disease must be measurable with at least 1 uni dimensional measurable lesion by
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

- Adequate hematological, hepatic and renal function as defined in the protocol

- Effective contraception for both male and female subjects if the risk of conception
exists

Other protocol-defined inclusion criteria could apply.

Exclusion Criteria:

- Concurrent treatment with non-permitted drugs and other interventions

- Anticancer treatment within 28 days before the start of trial treatment, for example
cyto reductive therapy, radiotherapy (with the exception of palliative radiotherapy
delivered in a normal organ-spearing technique), immune therapy, or cytokine therapy

- Major surgery within 28 days before the start of trial treatment (prior diagnostic
biopsy is permitted)

- Systemic therapy with immunosuppressive agents within 7 days before the start of trial
treatment; or use of any investigational drug within 28 days before the start of trial
treatment

- Previous malignant disease (other than the target malignancy to be investigated in
this trial) within the last 3 years. Subjects with history of cervical carcinoma in
situ, superficial or non invasive bladder cancer or basal cell or squamous cell cancer
in situ previously treated with curative intent are NOT excluded. Subjects with other
localized malignancies treated with curative intent need to be discussed with the
Medical Monitor.

- Rapidly progressive disease which, in the opinion of the Investigator, may predispose
to inability to tolerate treatment or trial procedures

- Subjects with active central nervous system (CNS) metastases causing clinical symptoms
or metastases that require therapeutic intervention are excluded

- Receipt of any organ transplantation, including allogeneic stem-cell transplantation,
but with the exception of transplants that do not require immunosuppression (eg,
corneal transplant, hair transplant)

Other protocol-defined exclusion criteria could apply
We found this trial at
49
sites
San Antonio, Texas 78258
Principal Investigator: Sharon Wilks
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Michael Lee
Phone: 919-966-4432
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1871 SE Tiffany Ave # 100
Port Saint Lucie, Florida 34952
Principal Investigator: Michael Wertheim
Phone: 772-408-5164
?
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Howard Safran
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
Athens, Georgia 30607
Principal Investigator: Petros Nikolinakos
?
mi
from
Athens, GA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Donald Harvey
Phone: 404-778-5849
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Rodolfo Bordoni
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Jason Melear
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bethesda, Maryland
Principal Investigator: James Gulley
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
6410 Rockledge Dr #660
Bethesda, Maryland 20817
(301) 571-0019
Principal Investigator: Ralph Boccia
Phone: 240-482-0523
Center for Cancer & Blood Disorders Widely recognized for its compassionate, expert care, the Center...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bethesda, Maryland 20817
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
18 Blacktown Road
Blacktown, New South Wales 2148
Principal Investigator: Mark Wong
Phone: +61286705070
?
mi
from
Blacktown,
Click here to add this to my saved trials
Boca Raton, Florida 33486
Principal Investigator: Edgardo Santos
Phone: 561-955-5630
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Osama Rahma
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Carolyn Britten
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
(312) 996-4350
Principal Investigator: Jonathan Moreira
Phone: 312-966-9272
University of Illinois at Chicago A major research university in the heart of one of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Oana Danciu
Phone: 312-996-2088
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45206
Principal Investigator: John Morris
Phone: 513-584-2951
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
216.844.8797
Principal Investigator: Jennifer Eads
Phone: 216-286-9210
Case Comprehensive Cancer Center The Case Comprehensive Cancer Center (Case CCC) based at Case Western...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Minal Barve
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Allen Cohn
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: Wang Ding
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Marwan Fakih
Phone: 626-218-0171
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Escondido, California 92025
Principal Investigator: Edward McClay
?
mi
from
Escondido, CA
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Principal Investigator: Alexander Spira
Phone: 703-280-5390
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Stephen Richey
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Goodyear, Arizona 85338
Principal Investigator: Glen Weiss
Phone: 480-132-3135
?
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: William Edenfield
Phone: 864-455-3735
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Nelson Yee
Phone: 717-531-0003
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Houston, Texas 77203
Principal Investigator: Julio Peguero
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Aung Naing
Phone: 713-794-4625
?
mi
from
Houston, TX
Click here to add this to my saved trials
Knoxville, Tennessee 37920
Principal Investigator: Russell DeVore
Phone: 865-934-2676
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
409 West Circle Drive
Lansing, Michigan 48910
Principal Investigator: Borys Hrinczenko
Phone: 517-975-9539
?
mi
from
Lansing, MI
Click here to add this to my saved trials
9280 W. Sunset Road Suite 100
Las Vegas, Nevada 89148
702.952.1251
Principal Investigator: Fadi Braiteh
Comprehensive Cancer Centers of Nevada Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning multidisciplinary...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Konstantin Dragnev
Phone: 603-650-4428
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Metairie, Louisiana 70006
Principal Investigator: Jayne Gurtler
?
mi
from
Metairie, LA
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Lynn Feun
Phone: 305-243-0863
?
mi
from
Miami, FL
Click here to add this to my saved trials
Newnan, Georgia 30265
Principal Investigator: Patricia Thompson
Phone: 770-400-7194
?
mi
from
Newnan, GA
Click here to add this to my saved trials
Norfolk, Virginia 23502
Principal Investigator: Paul Conkling
Phone: 757-213-5658
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Norwich, Connecticut 06360
Principal Investigator: Dennis Slater
Phone: 860-886-8362
?
mi
from
Norwich, CT
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Karen Kelly
Phone: 916-734-5930
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Benjamin Tan
Phone: 314-747-5376
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Kyriakos Papadopoulos
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
45 Castro Street
San Francisco, California 94114
(415) 600-6000
Principal Investigator: Ari Baron
Phone: 415-600-1775
California Pacific Medical Center California Pacific Medical Center is one of the largest private, not-for-profit,...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Tucson, Arizona 85712
Principal Investigator: Bruce Porterfield
Phone: 520-290-2510
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tyler, Texas 75702
Principal Investigator: Donald Richards
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Vancouver, Washington 98683
Principal Investigator: David Smith
?
mi
from
Vancouver, WA
Click here to add this to my saved trials
Westwood, Kansas 66205
Principal Investigator: Stephen Williamson
Phone: 913-945-5052
?
mi
from
Westwood, KS
Click here to add this to my saved trials
Whittier, California 90603
Principal Investigator: Agajanian Richy
Phone: 562-693-4477
?
mi
from
Whittier, CA
Click here to add this to my saved trials